A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis

Open Access

Peer-reviewed

Research Article

Keith Tolley ,

* E-mail: keith@tolleyhealtheconomics.com

Affiliation Tolley Health Economics Ltd., Buxton, United Kingdom
⨯
Michael Hutchinson,

Affiliation St. Vincent’s University Hospital, Dublin, Ireland
⨯
Xiaojun You,

Affiliation Biogen Idec Inc., Cambridge, MA, United States of America
⨯
Ping Wang,

Affiliation Biogen Idec Inc., Cambridge, MA, United States of America
⨯
Bjoern Sperling,

Affiliation Biogen Idec Inc., Cambridge, MA, United States of America
⨯
Ankush Taneja,

Affiliation HERON Commercialization—A Parexel Company, Chandigarh, India
⨯
Mohammed Kashif Siddiqui,

Affiliation HERON Commercialization—A Parexel Company, Chandigarh, India
⨯
Elizabeth Kinter

Affiliation Biogen Idec Inc., Cambridge, MA, United States of America
⨯

Reader Comments (0)

Interferons
Is the Subject Area "Interferons" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Network analysis
Is the Subject Area "Network analysis" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Multiple sclerosis
Is the Subject Area "Multiple sclerosis" applicable to this article?

Thanks for your feedback.
Comparators
Is the Subject Area "Comparators" applicable to this article?

Thanks for your feedback.
Disabilities
Is the Subject Area "Disabilities" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.